MMV’s pivotal Phase III study of fixed-dose combination antimalarial treatment of dihydroartemisinin and piperaquine with the contracted service of MDS Pharma Services has won the award, honouring excellence in clinical research.
This project shared the shortlist with two other projects in the category of "Clinical Research Programme that Best Promoted Access to Medicine". With over 2,650 patients involved in the trials in 8 countries across Africa and Asia, this is the first time such a major study, adhering to GCP and ICH standards, has been carried out to develop an antimalarial designed for the developing world. This project demonstrates the powerfully positive results that can emerge from public/private partnerships focused on neglected populations and unmet medical needs.
The winner was announced on September 6 at an annual gala event in London.